T Lahiri1, D A Waltz. 1. Division of Respiratory Diseases, Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: Although invasive pneumococcal disease is infrequent in cystic fibrosis (CF), it is recommended that all patients with CF receive pneumococcal immunization. As part of a comprehensive program to immunize our clinic population, we obtained preimmunization anti-pneumococcal antibody levels. We hypothesized that the percentage of CF patients without protective levels of anti-pneumococcal antibody levels would be high, as they are exposed to frequent antibiotic therapy that may eradicate organisms before generation of an antibody response. METHODS: An observational study of 100 patients with CF, aged 1 to 39 years, was conducted in a regional CF center. Preimmunization anti-pneumococcal antibody levels against 6 serotypes were measured by enzyme-linked immunosorbent assay. Protective antibody levels were defined as >200 ng/mL. RESULTS: A majority of CF patients-61% to 100%, depending on age and serotype-had protective levels of pneumococcal antibody. There was a significant positive correlation between antibody level and age for 5 of the 6 serotypes tested. CONCLUSIONS: In contradistinction to our hypothesis, the majority of CF patients have protective preimmunization anti-pneumococcal antibody levels. However, a significant proportion-between 17% and 39%, depending on the serotype-did not exhibit adequate levels. Therefore, we concur with current recommendations for pneumococcal immunization in CF.
OBJECTIVE: Although invasive pneumococcal disease is infrequent in cystic fibrosis (CF), it is recommended that all patients with CF receive pneumococcal immunization. As part of a comprehensive program to immunize our clinic population, we obtained preimmunization anti-pneumococcal antibody levels. We hypothesized that the percentage of CF patients without protective levels of anti-pneumococcal antibody levels would be high, as they are exposed to frequent antibiotic therapy that may eradicate organisms before generation of an antibody response. METHODS: An observational study of 100 patients with CF, aged 1 to 39 years, was conducted in a regional CF center. Preimmunization anti-pneumococcal antibody levels against 6 serotypes were measured by enzyme-linked immunosorbent assay. Protective antibody levels were defined as >200 ng/mL. RESULTS: A majority of CF patients-61% to 100%, depending on age and serotype-had protective levels of pneumococcal antibody. There was a significant positive correlation between antibody level and age for 5 of the 6 serotypes tested. CONCLUSIONS: In contradistinction to our hypothesis, the majority of CF patients have protective preimmunization anti-pneumococcal antibody levels. However, a significant proportion-between 17% and 39%, depending on the serotype-did not exhibit adequate levels. Therefore, we concur with current recommendations for pneumococcal immunization in CF.
Authors: Christine E Mathews; Eric L Brown; Perla J Martinez; Upasana Bagaria; Moon H Nahm; Robert L Burton; Susan P Fisher-Hoch; Joseph B McCormick; Shaper Mirza Journal: Clin Vaccine Immunol Date: 2012-07-03
Authors: Rosa del Campo; María-Isabel Morosini; Elia Gómez-G de la Pedrosa; Asunción Fenoll; Carmen Muñoz-Almagro; Luis Máiz; Fernando Baquero; Rafael Cantón Journal: J Clin Microbiol Date: 2005-05 Impact factor: 5.948
Authors: M Seki; Y Higashiyama; K Tomono; K Yanagihara; H Ohno; Y Kaneko; K Izumikawa; Y Miyazaki; Y Hirakata; Y Mizuta; T Tashiro; S Kohno Journal: Clin Exp Immunol Date: 2004-07 Impact factor: 4.330